Merck Unveils 20 Promising 'Blockbuster' Drugs in Pipeline with $50 Billion Potential

Fortune

Merck's recent earnings call highlighted a mix of growth and challenges for the pharmaceutical giant, with a focus on its robust pipeline of 20 new 'blockbuster' drugs in development, expected to generate a significant $50 billion in potential revenue, driving innovation in the pharmaceutical industry with cutting-edge treatments and medications, while navigating industry trends and market competition